China NMPA Drug Inspection - Jilin Xinhui Pharmaceutical Co., Ltd. - Traumatic Injury and Blood Circulation Powder

In August 2016, the State Administration for Market Regulation (formerly China Food and Drug Administration) issued an announcement regarding multiple batches of substandard drugs identified during national sampling inspections. Three pharmaceutical companies were implicated due to significant quality control deficiencies in their production processes. Hubei Ji'antang Pharmaceutical Co., Ltd. had four batches of its 'Snake Gallbladder and Fritillaria Liquid' identified as substandard concerning their identification properties. Jilin Xinhui Pharmaceutical Co., Ltd. was found to have three batches of 'Trauma and Blood Circulation Powder' failing content uniformity standards. Additionally, Sichuan Tongyuan Pharmaceutical Co., Ltd. had three batches of its 'Children's Cough and Asthma Relief Granules' deemed substandard based on their appearance. As a result of these findings, the provincial Food and Drug Administrations in Hubei, Jilin, and Sichuan were instructed to implement stringent measures. These included ordering the companies to immediately suspend production and sales, initiate product recalls, and face penalties in accordance with the 'Drug Administration Law of the People's Republic of China.' Furthermore, the companies are required to thoroughly investigate the root causes of these quality issues, implement comprehensive corrective actions, and are prohibited from resuming production until full rectification is confirmed. The regulatory bodies committed to publicly disclosing the progress of these actions.